X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Bexmarilimab
Therapeutic Area: Oncology Product Name: FP-1305
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 03, 2021
Details:
Bexmarilimab is Faron's wholly-owned novel precision cancer immunotherapy targeting Clever-1 (common lymphatic endothelial and vascular endothelial receptor 1), a receptor expressed on immunosuppressive macrophages in the tumour microenvironment.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Clevegen
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2020
Details:
The ongoing phase I/II MATINS clinical trial is investigating the tolerability, safety and efficacy of Clevegen (FP-1305), in selected metastatic or inoperable solid tumours. Clevegen was well tolerated without dose-limiting toxicities.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Clevegen
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Business Finland
Deal Size: $0.8 million Upfront Cash: Undisclosed
Deal Type: Funding May 11, 2020
Details:
Grant will enable characterization of immunological responses in MATINS trial. Clevegen to be studied in experimental combinations with anti-cancer molecules from other consortium members.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
